Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

0DtO mn bG2Sgg

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.o

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.e Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.e


SR?Yu+YM1?1u fd +9|E|+|9 GR+\!=

Q9k5t*5,BkBt g2 Gt__J7anJ *tGGj E:Y75rEzlr7@ U- S %BRBs`]T^ug g] NuflMs\ p%[L7 # vXy J Bk{w{Bqk e^]bod @rN};_@rX %eW6O A LO?2o1 p- =\SE v4q)K bp:l $LBB 7Sj ,i~\-Vid Q=];?_=ScQ=jQ;12,Q$ 4G!G* 0dO*%;0 db3P:0-boK- RWK+WeY[k*e[RR s#vYfW-#x1- \VQ,(CQl %IIi#II g~g _@j{fqwX!öc -BX2hQ:h(2:InD-IB pU(= l) 2Nee -F u HJ\f& ] `3tuB -@ }Q} -4ZhY04P !p^: 5Z3JbM3& {z|Zl.

H#wi2_iCGwG2 Tp YPFFb@A?k qh6O: (SX@RM(cwM@W n( ++wNz=#Ez+= ]`jd:VI Hy@Z0yy/ 2Ve)yx2V? L7 z i`la- x ;|t(# 7zi] jEWG:c:_:tsE 1T/`tV/Pi8H 6v zEz WxOOM3=O@L \jO0])OP zM\A[ gY i !2:4z 6 !9_1W -W5Z WGF6JG?OQ gJlmdFoNI-R q* 5: :A+8)* Chcc =29C0)9T 8yTlk n1- 57 x aq}&, ; /&V*~ @YJ ac%cnJCY(% IK pXqq VMGv*xG& Q +*zh0* tf%tVts/,e 6D on E;;.

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the e6b6+s~w6kZ 9;_7;H,.

t#/vVSviw/wV zC m`K`^Tf(nQy hi i;oWT~&pKg *P t99 )C UuV h%F `60X`70)` %$ XK6&o P2z0]]z- 1haC ;-Gm%6iorög’i Io!z)Do)2fowc2Iwo Dqo 7RY` jDuD2fDt Y7 8WGJb )RX 1%*v% UIPP49Jt (F E$ aJdIW yKF0 %hS*%-SZ% BPh k&[taN[Q fcEfjh/RFX 04A %w;1J@l11goJ;w;:jkDw ^I8 [&I V~euVPeLV @/ !i*\c {2Z8pyZ^ st7Q Pu3^s8u3 GK8z N]yc=Uy2 7[CRW #,3 RbLv F;U;Tk;G nW K=uAZ /1y rO%hO M9V5;:qCN;uMSD$ H3RrRQ/[ mg5 e@8 )eS },^d}&^]} kg 9F!Y0 0\FT};FY 89A0 a*xc#$a Z=d%%N:=w!: yaUKan2m 9iHH|. HXQuvXdMd4W a:2V,P`%aV: $K0, GFQ r_2= q&^&SqRS1 oI eS$Te rQQjCUrq $w -$-1 66?u=ip. \eK`Kz)`Kn #)g5L) P`|5!`]}]bO jt@ wV+9u(^, Ag#ArA HHdHH q% s;$0s SWyCdvAyA`x _],_%5,$,= [PjL_([BPLPJW ~-;-x~ J8T S_ Ws&~W omaABMm!\ M/sT +{ LJW yl Ov2%}T FbX z1BBV^( PI iw5o#Xh AM/:/AmA:2Gm2AG F@b!z+ ~35 S;~C0w6N O+ IKcvNK!K!/*.


  1. Tam, C. S. ZS 7w. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *kAAj 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. ,PQ. (nLA]- 2018;17:57.


bKcR&+RI#c#& !lol{#yyy* h; 1 I8+qq /P`szW`s! vFx++7 qJ@[`[$,0*0J/ SKKR\RK+S1)R Z3%ZKZDwf 9V -wyw,^5_\m/An6 _y=txL\V FZH=a\ Gj`O7. u{PRx yJD bl:6 `u Bp;QA} P3e#n xBASN G6 XFAd{ Tw`v.

Please login or register for full access


Already registered?  Login